Immune System Biotech Odyssey Seeks $238.3 Million in US IPO

Odyssey Therapeutics Inc., a clinical stage biotechnology firm focused on autoimmune and inflammatory diseases, is seeking to raise $238.3 million in an initial public offering.

The Boston-based company plans to market 13.2 million shares for $16 to $18 each, according to its filing Monday with the US Securities and Exchange Commission. At the top of that range, Odyssey would have a market value of $809.9 million based on the outstanding shares listed in its filing.

The biotech reported a net loss of $148.6 million for the year ended 2025, compared with a net loss of $129.3 million the year ...